Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.
Phase 2
Recruiting
- Conditions
- Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.
- Registration Number
- JPRN-UMIN000012472
- Lead Sponsor
- Epidemiological and Clinical Research Information Network (ECRIN)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Concurrent malignancy other than CML 2.Women who are pregnant or breastfeeding 3. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy 4.Subjects with clonal evolution
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Molecular relapse free survival rate after discontinuation of Imatinib at 6 months.
- Secondary Outcome Measures
Name Time Method Molecular relapse free survival rate after discontinuation of Imatinib at 12,24 months. We assessed previous interferon therapy, sex , sokal risk group and total duration of Imatinib treatment as potential prognostic factors for molecular relapse free survival. CMR rate and time to CMR of PCR+ patients by PCR screening after dasatinib treatment. CMR rate and time to CMR of dasatinib treatment after molecular relapse.